Home » Boston Scientific Suffers Losses Due to Shipment Hold on ICDs
Boston Scientific Suffers Losses Due to Shipment Hold on ICDs
A month-long shipment hold on implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators is expected to cost Boston
Scientific $300 million this year. The company reported last week that it had lost $72 million in the first quarter alone due to the hold. However, Boston
Scientific expects to benefit from a projected 3 percent to 5 percent growth in the global cardiac rhythm device market.
Devices & Diagnostics Letter
Devices & Diagnostics Letter
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May